TRUE Private Wealth Advisors Acquires 2,165 Shares of Pfizer Inc. (NYSE:PFE)

TRUE Private Wealth Advisors increased its holdings in Pfizer Inc. (NYSE:PFE) by 3.5% in the fourth quarter, Holdings Channel reports. The institutional investor owned 63,723 shares of the biopharmaceutical company’s stock after buying an additional 2,165 shares during the period. TRUE Private Wealth Advisors’ holdings in Pfizer were worth $1,691,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in PFE. Nordea Investment Management AB grew its stake in Pfizer by 36.1% during the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company’s stock worth $108,002,000 after buying an additional 1,080,822 shares in the last quarter. Parsons Capital Management Inc. RI grew its stake in shares of Pfizer by 118.7% during the fourth quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock worth $7,820,000 after buying an additional 159,984 shares during the last quarter. Copley Financial Group Inc. acquired a new position in Pfizer in the 3rd quarter worth about $577,000. Geode Capital Management LLC raised its position in Pfizer by 1.6% in the third quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company’s stock valued at $3,392,342,000 after purchasing an additional 1,855,419 shares during the last quarter. Finally, Mcdonald Partners LLC increased its stake in shares of Pfizer by 9.9% in the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company’s stock valued at $2,926,000 after buying an additional 9,963 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Down 3.9 %

Shares of NYSE:PFE opened at $21.75 on Wednesday. The firm has a fifty day moving average of $25.59 and a 200 day moving average of $26.58. Pfizer Inc. has a 52-week low of $20.89 and a 52-week high of $31.54. The firm has a market capitalization of $123.33 billion, a PE ratio of 15.42, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the previous year, the firm posted $0.10 EPS. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of several analyst reports. Bank of America reissued a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. UBS Group reduced their price objective on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a research report on Tuesday. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Finally, Truist Financial dropped their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $31.07.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.